IPP Bureau

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

By IPP Bureau - April 04, 2026

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy

Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma
Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

By IPP Bureau - April 04, 2026

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

Jan Vishwas Bill 2026 decriminalises minor health sector offences, eases compliance burden
Jan Vishwas Bill 2026 decriminalises minor health sector offences, eases compliance burden

By IPP Bureau - April 04, 2026

Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws

ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses

By IPP Bureau - April 03, 2026

Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology

Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment
Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment

By IPP Bureau - April 03, 2026

The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

By IPP Bureau - April 03, 2026

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra

By IPP Bureau - April 03, 2026

Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

By IPP Bureau - April 03, 2026

Its a major breakthrough for women’s ovarian cancer care in Europe

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

By IPP Bureau - April 03, 2026

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year

Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells

By IPP Bureau - April 03, 2026

The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells

Nearly 40 industry groups unite to push for EU Biotech Act II
Nearly 40 industry groups unite to push for EU Biotech Act II

By IPP Bureau - April 03, 2026

A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer

By IPP Bureau - April 03, 2026

The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)

EMA moves to cut animal testing with “virtual control groups” in preclinical research
EMA moves to cut animal testing with “virtual control groups” in preclinical research

By IPP Bureau - April 03, 2026

The approach, which could significantly reduce the number of rats used in certain dose-range finding studies

Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies
Biocytogen and Sihuan Pharmaceutical forge strategic pact to accelerate antibody-based therapies

By IPP Bureau - April 03, 2026

The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development

Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Cardinal Health boosts production of cutting-edge cancer therapy ingredient

By IPP Bureau - April 03, 2026

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.

Latest Stories

Interviews

Packaging